Infinity Pharmaceuticals, Inc. (INFI)


-0.01 (-52.38%)
Symbol INFI
Price $0.008
Beta 1.380
Volume Avg. 3.98M
Market Cap 0.726M
Shares () -
52 Week Range 0.0056-1.3
1y Target Est -
DCF Unlevered INFI DCF ->
DCF Levered INFI LDCF ->
ROE 166.89% Strong Buy
ROA -187.96% Strong Sell
Operating Margin -
Debt / Equity -1.69% Neutral
P/E -0.02 Neutral
P/B -0.02 Neutral


Consensus EPS

Upgrades & Downgrades

Latest INFI news

Mr. Seth A. Tasker J.D.
NASDAQ Global Select

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.